Triptorelin, a synthetic decapeptide and analog of natural gonadotropin-releasing hormone (GnRH), has gained significant recognition in the medical field. It is used for various indications, including the treatment of endometriosis, fibroids, prostate cancer, precocious puberty, and infertility. Triptorelin acts by initially stimulating the secretion of gonadotropins and subsequently downregulating gonadotropin-releasing hormone receptors, resulting in long-term reduction of gonadotropin release.
Triptorelin exhibits a broad range of therapeutic effects. In women, it is utilized to manage endometriosis, uterine fibroids, and infertility. Triptorelin's continuous administration effectively inhibits the production of estradiol, leading to the suppression of ectopic endometrial tissue in endometriosis. Additionally, studies have shown a significant reduction in the size of uterine fibroids, with most patients experiencing amenorrhea after the first month of treatment. For infertility, triptorelin inhibits the secretion of gonadotropins, improving the quality of follicle production and increasing the number of follicles, thereby enhancing the chances of successful assisted reproductive techniques like in vitro fertilization.
In men, triptorelin is commonly used for the management of prostate cancer. It acts by initially increasing blood luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, followed by a decrease in these hormones and a subsequent decrease in blood testosterone levels. This reduction in testosterone levels helps in the treatment of prostate cancer and its associated symptoms. Triptorelin injections have also been effective in the treatment of precocious puberty, inhibiting pituitary hypersecretion of gonadotropins and normalizing hormone levels.
The mechanisms of action of triptorelin involve both the suppression of gonadotropin secretion and direct gonadotropic inhibition by desensitizing peripheral GnRH receptors. Animal and human studies have demonstrated the inhibitory effects of chronic triptorelin use on gonadotropin secretion, leading to the suppression of testicular and ovarian function. Triptorelin's effectiveness is further evidenced by clinical improvements in symptoms such as dysmenorrhea, chronic pelvic pain, and pain during sexual intercourse.
We provide a variety of customized solutions for you to choose from
Triptorelin injection: 0.1 mg/1 ml.
Triptorelin extended-release injection: 3.75 mg; 11.25 mg; 22.5 mg.
Triptorelin pamoate for injection: 15 mg per bottle (containing 1 bottle of 2 ml solvent). If you have other needs, you can also contact us and we will provide you with immediate and precise customization services.
As a potent gonadotropin analog,Triptorelin offers a range of therapeutic applications for both men and women. Its ability to regulate hormone levels and inhibit gonadotropin secretion has proven effective in managing conditions such as endometriosis, uterine fibroids, prostate cancer, precocious puberty, and infertility. With its clinical efficacy and versatility, triptorelin continues to contribute significantly to the field of reproductive medicine and oncology.Understanding the mechanisms of action and available preparations of triptorelin allows healthcare professionals to tailor treatment plans to individual patient needs.
